May 2009

May
2009
Vol. 21. No. 2

EDITORIAL

AACP provides you with vital clinical information in print, online, and in person

The partnership between the American Academy of Clinical Psychiatrists (AACP) and Dowden
Health Media announced in February 2009 got off to a great start with our fi rst jointly sponsored educational meeting, “Bipolar disorder and ADHD: Solving clinical challenges, improving patient care,” held in Chicago in April. Th e well-attended and lively event attracted clinicians from around the country who heard from leading experts about how to care for patients with bipolar disorder, attention defi cit/hyperactivity disorder, or both. I saw many old friends and made new ones, all enthusiastic about the redesigned Annals of Clinical Psychiatry.

MORE

ORIGINAL RESEARCH

Escitalopram reduces hot flashes in nondepressed menopausal women: A pilot study

Roseanne DeFronzo Dobkin, PhD | Matthew Menza, MD | Lesley A. Allen, PhD | Humberto Marin, MD | Karina L. Bienfait, PhD | Jade Tiu, BA | Jennifer Howarth, BA

BACKGROUND: Hot fl ashes are one of the most troubling manifestations of menopause, affecting about 80% of women. Due to recent controversies about hormone replacement therapy, many women seek alternative treatments. Th e use of antidepressants to treat hot flashes and other menopausal symptoms has been an active area of investigation. However, the majority of past research in this area has included women with significant medical or psychiatric histories that may infl uence treatment response. Th is was the fi rst study to examine the impact of escitalopram on hot fl ashes, mood, sleep, and quality of life in a sample of healthy nondepressed menopausal women.

MORE

3 case reports of edema associated with quetiapine

Hristina K. Koleva,, MD | Mark A. Erickson, BS | Erik R. Vanderlip, MD | Janeta Tansey, MD, PhD | Joseph Mac, PharmD | Jess G. Fiedorowicz, MD, MS

BACKGROUND: Edema associated with quetiapine has been described in only one case report to date and represents a potentially serious adverse reaction.

MORE

Anxiety symptom severity and functional recovery or relapse

Dan J. Stein, FRCPC, PhD | Borwin Bandelow, MD | Ornah T. Dolberg, MD | Henning F. Andersen, MSc | David S. Baldwin, MD

BACKGROUND: Anxiety disorders are associated with significant disability. There is growing interest in the question of whether pharmacotherapy that effectively reduces symptoms can also restore function. Recovery could potentially be defined as a lack of disability, with an associated reduction in symptom severity. Conversely, relapse could potentially be defined in terms of either increased disability or increased symptoms.

MORE

A preliminary controlled trial of divalproex in posttraumatic stress disorder

Mark B. Hamner , MD | Richard A. Faldowski, PhD | Sophie Robert , PharmD | Helen G. Ulmer, MSN | Michael David Horner, PhD | Jeffrey P. Lorberbaum, MD

BACKGROUND: Case reports and open trials have reported beneficial effects of divalproex in the treatment of posttraumatic stress disorder (PTSD). Th e objective of this study was to conduct a placebo-controlled study of the efficacy and tolerability of divalproex in chronic PTSD patients.

MORE